AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

被引：42

作者：

De Gramont, A.

Van Cutsem, E.

Tabernero, J.

Moore, M. J.

Cunningham, D.

Rivera, F.

Im, S.

Makrutzki, M.

Shang, A.

Hoff, P. M.

机构：

[1] Hop St Antoine, F-75571 Paris, France

[2] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[3] Vail dHebron Univ Hosp, Barcelona, Spain

[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[5] Royal Marsden Hosp, Sutton, Surrey, England

[6] Hosp Marques de Valdecilla, Santander, Spain

[7] Seoul Natl Univ Hosp, Seoul 110744, South Korea

[8] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[9] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil

来源：

关键词：

D O I：

10.1200/jco.2011.29.4_suppl.362

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

362

引用

页数：1